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take into consideration cosmetic and functional demands. Mohs micrographic surgery is favoured because it precisely identifies tumour-free margins while sparing normal tissue, thus optimizing cosmetic and functional outcomes [5] [6] [7] . In our patients, photodynamic therapy (PDT) was chosen either because of a previous failure of topical therapy (imiquimod, 5-fluorouracil) or in case of recurrence after surgery, when the patient declined repeat surgery, as well as first-line therapy in 5 patients.
Photodynamic Treatment Protocol of the Glans Penis
Methylaminolaevulinate 160 mg/g of vehicle (MAL) was applied for 3 h under an occlusive dressing to the glans penis covering the affected area as well as a 5-mm margin of clinically normal surrounding tissue. Before illumination, a local anaesthetic penile ring block using 2% lidocaine without adrenalin was applied. The affected areas were then illuminated using a non-coherent red light source (Waldmann PDT 1200L, 570-670 nm) with a total dose of 75 J/cm 2 . The therapeutic response was evaluated clinically at regular intervals as well as by fluorescence dynamic diagnosis (FDD) in a subgroup of patients.
Case Reports
A total of 11 patients with EQ affecting the glans penis were treated by PDT. The patients' characteristics are summarized in table 1 . In all cases the diagnosis was confirmed by histology before PDT. In some cases, the clinical follow-up was documented with photographs ( fig. 1 ). All male patients were aged 49-87 years at diagnosis (mean 69 years). For 5 patients, PDT was the first-line treatment (patients No. 3, 5, 6, 8 and 11), while the other patients had already undergone treatment with topical imiquimod (patients 1, 2, 7, 9 and 10), topical 5-fluorouracil (patients 1 and 10), carbon dioxide laser (patient 4) or circumcision (patient 1, 2, 4 and 7). The patients underwent between 2 and 19 PDT treatment sessions (mean 8 sessions). The interval between 2 sessions varied from 1 to 48 weeks.
Out of 11 patients, 3 achieved a long-term complete response sustained for 24 and 51 months (patients 1-3), respectively, and 4 a partial remission (patients 4-7, clinically residual small red plaque) sustained for 2-45 months with a follow-up period of 4-45 months (1 patient lost to follow-up). Histological confirmation of remission was obtained in 2 cases (patients 3 and 6). It is noteworthy that 2 of the 3 patients with complete remission had been resistant to previous treatments. Surprisingly, 2 of the 4 patients with partial remission after PDT (patients 6 and 7) presented a complete remission after 20 and 45 months of follow-up, respectively, without further therapy. Retrospectively, as no confirmation biopsy was performed immediately after the end of treatment in these patients, the redness interpreted as residual disease may have been only a side effect of therapy. Four patients showed a progression (patients 9 and 10) or did not tolerate the therapy (patients 8 and 11). Five patients required another therapeutic modality subsequently (patients 4 and 8-11). FDD was used in 4 patients (patients 1, 2, 5 and 7) and compared to the clinical evaluation of residual disease. FDD correlated only partly with the clinical assessment: in the 4 patients where FDD was performed, 3 showed a correlation with the clinical status whereas in patient 7, FDD showed no fluorescence while a red macula was clinically visible on his mucosa. In 2 cases (patients 3 and 6), a biopsy was performed just after, respectively, at a distance to the end of therapy because of a suspicion of recurrence: neither histology showed signs of malignant transformation. This suggests that the evaluation of the outcome is clinically difficult.
The mean number of PDT sessions was 12.3 in the complete response, 10.3 in the partial remission group, whereas it was only 2.8 in the progression group.
Most patients experienced erythema and mild to moderate burning at the site of application during illumination, followed by mild swelling. Reported adverse effects included discomfort associated with dysuria, which subsided over the following 1-3 days before it resolved completely (patients 2, 3, 6 and 7). Haematoma at the site of PDT was reported by patient No. 3. Patients 8 and 11 had to stop PDT because of adverse events: both had a very painful inflammatory reaction after 2 sessions. Three patients (No. 1, 4 and 5) reported no adverse events. No information on adverse events was available for 2 patients (No. 9 and 10). 
Discussion
The treatment options for EQ reported in the literature are numerous as listed in table 2 . MAL-based PDT -depending on the country -is a registered treatment for superficial basal cell carcinoma, Bowen's disease and actinic keratosis and a reported treatment option for squamous cell carcinoma [28] . Topical MAL-PDT combines MAL, which is converted into protoporphyrin IX within cells, and visible light to produce a photodynamic effect in the presence of oxygen, resulting in the formation of cytotoxic reactive oxygen species. It leads to a selective destruction of abnormal cells while preserving normal cells and results in an excellent cosmetic outcome. PDT is a highly effective therapy for the treatment of Bowen's disease, a carcinoma in situ affecting the outer skin and similar in histology and presentation to EQ with complete remission in approximately 90% of patients treated and partial remission in 7.5% of patients treated [29, 30] .
We present 11 patients with EQ who were treated by topical MAL-PDT. Of 11 patients, 3 achieved a complete response, 4 a partial remission, and 4 had a progression of disease. Whereas 5 patients required a subsequent therapeutic modality following MAL-PDT, PDT was a very satisfactory therapy for 5 other patients (1 patient lost to follow-up). Of note, the 4 patients who underwent circumcision before PDT seemingly showed a better outcome with 2 complete and 2 partial remissions. Others have reported on the use of PDT in EQ with similar results: Stables et al. [8] reported 4 patients with EQ treated by topical 5-aminolaevulinic acid PDT. Of 2 patients with limited disease, 1 achieved a long-term complete response (36 months) after a single cycle of treatment and the other remained free of disease for 18 months after the second treatment. Two further patients with more extensive disease achieved partial response after 2 cycles of 5-aminolaevulinic acid PDT and required laser vaporization [8] . Lee and Ryman [9] reported an 82-year-old patient with invasive squamous cell carcinoma of the glans penis arising in EQ. While he underwent Mohs micrographic surgery for his invasive carcinoma, his residual EQ was treated by PDT. Eighteen weeks after completion of one cycle of treatment, he had no evidence of recurrence [9] .
Although the small number of reported cases (5 patients to date [8, 9] ) does not allow a relevant statistical comparison of the success of this therapy, our results document a favourable outcome after PDT for some of the patients and underline the importance of repeated treatment. Indeed, the mean number of PDT sessions in our patient collective was 12.3 in the complete response group, 10.3 in the partial remission group, whereas it was only 2.8 in the progression group. The patients of Stables et al. [8] had 1-2 cycles, that of Lee and Ryman [9] 1 cycle of therapy only. We think therefore that the success of the PDT therapy for EQ is closely linked to the number of sessions, and that patients treated by this method need to be regularly followed clinically. We believe that PDT provides a valuable option for selected cases like patients encountering recurrence after surgery, or in patients where conservative treatment is preferred to surgery. The main advantages of PDT are the good tolerability with limited adverse events in comparison to more invasive treatments [31] as well as the good cosmetic result. Nevertheless, side effects may cause treatment discontinuation in some cases. The main drawbacks are the high recurrence rate which mandates a regular clinical follow-up as well as the time-consuming treatment.
Conclusion
There have only been few reports on 5-aminolaevulinic acid -PDT in the treatment of EQ. We provide here clinical data on MAL-PDT for EQ as a viable treatment for half of our 11 patients. However, complete remission immediately after therapy has been achieved in 3 patients only. Two of the 4 patients with partial remission after PDT presented a complete remission at the follow-up, without further therapy. The redness interpreted as residual disease may have been only a side effect of therapy. Four patients were non-responders, requiring further treatment.
Our results indicate that treatment of EQ with MAL-PDT may represent a valuable option in selected cases of histologically confirmed EQ, with preserved function and good cosmetic outcome. However, our data do not allow considering it as a first-line therapeutic recommendation. Data from the literature also report inconsistent success. In conclusion, PDT may have a favourable outcome for some patients with EQ, but long-term efficacy and safety should be assessed on a larger clinical basis. Long-term follow-up is important to recognize and treat relapses at an early time point.
